EDAP

Edap Tms SA

Add to Watchlist

Advanced Chart

1.350

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.482

Open

1.310

VWAP

1.43

Vol

46.29K

Mkt Cap

50.48M

Low

1.310

Amount

66.31K

EV/EBITDA(TTM)

Total Shares

37.10M

33.69M

EV/OCF(TTM)

P/S(TTM)

0.76

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

16.60M

-5.86%

13.53M

-3.76%

19.41M

-11.43%

Estimates Revision

The market is revising No Change the revenue expectations for EDAP TMS S.A. (EDAP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.73%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-23.73%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast EDAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDAP is 5.67 USD with a low forecast of 1.50 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 1.350

Low

1.50

Averages

5.67

High

14.00

Current: 1.350

Low

1.50

Averages

5.67

High

14.00

H.C. Wainwright

Buy

downgrade

$19 -> $14

2025-05-16

Reason

H.C. Wainwright

Price Target

$19 -> $14

2025-05-16

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on EDAP TMS to $14 from $19 and keeps a Buy rating on the shares following the Q1 report. The firm accounts for management's de-emphasizing the noncore businesses.

Piper Sandler

Overweight -> Neutral

downgrade

2025-05-15

Reason

Piper Sandler

Price Target

2025-05-15

downgrade

Overweight -> Neutral

Reason

Piper Sandler downgraded EDAP TMS to Neutral from Overweight with a price target of $1.50, down from $4.50. The downgrade is "less about 1Q results," which were "fine even if not spectacular," and more about the operational and financial challenges the firm sees over the next year, the analyst tells investors.

Jefferies

Michael Sarcone

Strong Buy

Hold

Downgrades

$8 → $2

2025-04-04

Reason

Jefferies

Michael Sarcone

Price Target

$8 → $2

2025-04-04

Downgrades

Strong Buy

Hold

Reason

Jefferies downgraded EDAP TMS to Hold from Buy with a price target of $2, down from $8. The firm sees downside to consensus estimates. While the company's high intensity focused ultrasound sales should growth in the mid-teens range, consensus expects higher, leaving numbers too high in the near to mid-term, the analyst tells investors in a research note. Jefferies does not incorporate sales from endometriosis or benign prostatic hyperplasia applications for EDAP TMS, citing regulatory and timeline uncertainty.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$19

2025-03-28

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$19

2025-03-28

Reiterates

Strong Buy

Reason

Piper Sandler

Jason Bednar

Buy

Maintains

$5 → $4.5

2025-03-28

Reason

Piper Sandler

Jason Bednar

Price Target

$5 → $4.5

2025-03-28

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on EDAP TMS to $4.50 from $5 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 results, including revenue of $21.5M/+1.1% year-over-year vs. Street's $21M/PSC $20.9M, confirming Piper's view that above-expected revenue was likely after learning in January the sales team locked in a record Focal One quarter. The firm continues to see EDAP as undervalued at current levels.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$19

2024-08-29

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$19

2024-08-29

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Edap Tms SA (EDAP.O) is -2.14, compared to its 5-year average forward P/E of -45.60. For a more detailed relative valuation and DCF analysis to assess Edap Tms SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-45.60

Current PE

-2.14

Overvalued PE

110.88

Undervalued PE

-202.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-63.38

Current EV/EBITDA

-1.53

Overvalued EV/EBITDA

134.21

Undervalued EV/EBITDA

-260.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

3.35

Current PS

0.80

Overvalued PS

4.80

Undervalued PS

1.90